We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 355

Biotech companies struggling in public markets
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand


Ohio sees growth in biosciences sector
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Bioscience jobs in Ohio have reportedly grown nearly 20 percent in the past decade and represent 62,500 workers, according to a report from BioOhio, a biomedical advocacy group


Biosimilars market expected to increase by billions over next four years
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Market analysts have apparently forecast huge growth in the market for biosimilars due to the upcoming loss of patent exclusivity for a number of branded drugs


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

The U.S. Patent & Trademark Office implements prioritized examination of patent applications


News bytes - March 7, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • March 7 2013

The U.S. Patent and Trademark Office (USPTO) seeks public comments by May 3, 2013, on "information requirements related to civil actions and claims


FDA targets “high-risk” compounding pharmacies for inspection
  • Shook Hardy & Bacon LLP
  • USA
  • March 7 2013

The Food and Drug Administration (FDA) has reportedly begun focusing its investigative efforts on compounding pharmacies at "high risk" for


SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


Biotech set to raise $86 million in IPO to support cancer and IEM products
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Agios Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up to


FDA seeks comments on de-identified and masked data
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Food and Drug Administration (FDA) has issued a notice seeking comments on "the proposed availability of de-identified and masked data


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe